Please use this identifier to cite or link to this item:
https://doi.org/10.1371/journal.pone.0090909
DC Field | Value | |
---|---|---|
dc.title | Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma | |
dc.contributor.author | Chow, P.K.H. | |
dc.contributor.author | Poon, D.Y.H. | |
dc.contributor.author | Khin, M.-W. | |
dc.contributor.author | Singh, H. | |
dc.contributor.author | Han, H.-S. | |
dc.contributor.author | Goh, A.S.W. | |
dc.contributor.author | Choo, S.-P. | |
dc.contributor.author | Lai, H.-K. | |
dc.contributor.author | Lo, R.H.G. | |
dc.contributor.author | Tay, K.-H. | |
dc.contributor.author | Lim, T.-G. | |
dc.contributor.author | Gandhi, M. | |
dc.contributor.author | Tan, S.-B. | |
dc.contributor.author | Soo, K.-C. | |
dc.date.accessioned | 2016-06-01T10:33:02Z | |
dc.date.available | 2016-06-01T10:33:02Z | |
dc.date.issued | 2014-03-10 | |
dc.identifier.citation | Chow, P.K.H., Poon, D.Y.H., Khin, M.-W., Singh, H., Han, H.-S., Goh, A.S.W., Choo, S.-P., Lai, H.-K., Lo, R.H.G., Tay, K.-H., Lim, T.-G., Gandhi, M., Tan, S.-B., Soo, K.-C. (2014-03-10). Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma. PLoS ONE 9 (3) : -. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0090909 | |
dc.identifier.issn | 19326203 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/124882 | |
dc.description.abstract | Background: The safety and tolerability of sequential radioembolization- sorafenib therapy is unknown. An open-label, single arm, investigator-initiated Phase II study (NCT0071279) was conducted at four Asia-Pacific centers to evaluate the safety and efficacy of sequential radioembolization-sorafenib in patients with hepatocellular carcinoma (HCC) not amenable to curative therapies. Methods: Sorafenib (400 mg twice-daily) was initiated 14 days post-radioembolization with yttrium-90 (90Y) resin microspheres given as a single procedure. The primary endpoints were safety and tolerability and best overall response rate (ORR) using RECIST v1.0.Secondary endpoints included: disease control rate (complete [CR] plus partial responses [PR] and stable disease [SD]) and overall survival (OS). Results: Twenty-nine patients with Barcelona Clinic Liver Cancer (BCLC) stage B (38%) or C (62%) HCC received a median of 3.0 GBq (interquartile range, 1.0) 90Y-microspheres followed by sorafenib (median dose/day, 600.0 mg; median duration, 4.1 months). Twenty eight patients experienced ≥1 toxicity; 15 (52%) grade ≥3. Best ORR was 25%, including 2 (7%) CR and 5 (18%) PR, and 15 (54%) SD. Disease control was 100% and 65% in BCLC stage B and C, respectively. Two patients (7%) had sufficient response to enable radical therapy. Median survivals for BCLC stage B and C were 20.3 and 8.6 months, respectively. Conclusions: This study shows the potential efficacy and manageable toxicity of sequential radioembolization- sorafenib. Trial Registration: ClinicalTrials.gov NCT00712790. © 2014 Chow et al. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1371/journal.pone.0090909 | |
dc.source | Scopus | |
dc.type | Article | |
dc.contributor.department | DUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE | |
dc.contributor.department | SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH | |
dc.contributor.department | SURGERY | |
dc.description.doi | 10.1371/journal.pone.0090909 | |
dc.description.sourcetitle | PLoS ONE | |
dc.description.volume | 9 | |
dc.description.issue | 3 | |
dc.description.page | - | |
dc.description.coden | POLNC | |
dc.identifier.isiut | 000332839300052 | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
2014-multicenter_phase_II_study_of_sequential-published.PDF | 631.4 kB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.